Pfizer
Amit Garg is an experienced professional in the field of clinical pharmacology, holding leadership positions at notable pharmaceutical companies. Currently serving as Executive Director and previously as Senior Director of Clinical Pharmacology Oncology at Pfizer from December 2023 to January 2024, Amit has extensive experience at Seagen as Senior Director of Quantitative Pharmacology and Disposition from April 2019 to December 2023. Previous roles include Senior Scientist and Scientist at Genentech from July 2010 to April 2019 and Senior Research Pharmacokineticist at Merck from August 2007 to July 2010. Amit earned a Ph.D. in Pharmacokinetics & Pharmacodynamics from the University at Buffalo and a M.S. in Pharmaceutics from the Massachusetts College of Pharmacy and Health Sciences.
This person is not in any teams
This person is not in any offices
Pfizer
614 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.